[go: up one dir, main page]

ATE393917T1 - Identifikation von therapeutische verbindungen. - Google Patents

Identifikation von therapeutische verbindungen.

Info

Publication number
ATE393917T1
ATE393917T1 AT04717679T AT04717679T ATE393917T1 AT E393917 T1 ATE393917 T1 AT E393917T1 AT 04717679 T AT04717679 T AT 04717679T AT 04717679 T AT04717679 T AT 04717679T AT E393917 T1 ATE393917 T1 AT E393917T1
Authority
AT
Austria
Prior art keywords
identification
therapeutic compounds
efficacy
therapeutic agents
potential therapeutic
Prior art date
Application number
AT04717679T
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Application granted granted Critical
Publication of ATE393917T1 publication Critical patent/ATE393917T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
AT04717679T 2003-03-07 2004-03-05 Identifikation von therapeutische verbindungen. ATE393917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0305153.9A GB0305153D0 (en) 2003-03-07 2003-03-07 Identification of therapeutic compounds

Publications (1)

Publication Number Publication Date
ATE393917T1 true ATE393917T1 (de) 2008-05-15

Family

ID=9954251

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04717679T ATE393917T1 (de) 2003-03-07 2004-03-05 Identifikation von therapeutische verbindungen.

Country Status (15)

Country Link
US (1) US20070059773A1 (de)
EP (1) EP1604211B1 (de)
JP (1) JP4701330B2 (de)
AT (1) ATE393917T1 (de)
AU (1) AU2004217731B2 (de)
CA (1) CA2514338A1 (de)
CY (1) CY1108540T1 (de)
DE (1) DE602004013431T2 (de)
DK (1) DK1604211T3 (de)
ES (1) ES2305741T3 (de)
GB (1) GB0305153D0 (de)
PL (1) PL1604211T3 (de)
PT (1) PT1604211E (de)
SI (1) SI1604211T1 (de)
WO (1) WO2004079329A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
MXPA06010075A (es) * 2004-03-05 2007-04-10 Cambridge Biotechnology Ltd Compuestos terapeuticos.
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN101330909B (zh) 2005-11-30 2012-09-26 坎-菲特生物药物有限公司 A3腺苷受体激动剂在制备治疗骨关节炎的药物中的应用
AU2007263727A1 (en) 2006-06-27 2008-01-03 Biovitrum Ab (Publ) 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor
US7807685B2 (en) 2006-06-27 2010-10-05 Cbt Development Limited Therapeutic compounds
EP2613277A1 (de) * 2012-01-06 2013-07-10 MathPharm GmbH Verfahren und System zur Identifikation von Verbindungen, die einen Zielopioidrezeptor abhängig vom pH-Wert binden und vorzugsweise aktivieren
US10441541B2 (en) * 2015-09-14 2019-10-15 New York University Methods and compositions for treating osteoarthritis and promoting cartilage formation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2359536C2 (de) * 1972-12-08 1984-08-02 Takeda Chemical Industries, Ltd., Osaka 2,6-Diaminonebularinderivate
JPS5461195A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
US4705758A (en) * 1984-06-19 1987-11-10 Warner-Lambert Company Adenosine receptor assay and kit
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
US5104859A (en) * 1985-09-24 1992-04-14 Solimedco Aktiebolag Continuous administration of adenosine to reduce pulmonary vascular resistance
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US6180616B1 (en) * 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
IT1275420B (it) * 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds

Also Published As

Publication number Publication date
EP1604211A2 (de) 2005-12-14
DK1604211T3 (da) 2008-09-08
WO2004079329A3 (en) 2004-12-09
DE602004013431T2 (de) 2009-06-25
JP2006519602A (ja) 2006-08-31
JP4701330B2 (ja) 2011-06-15
AU2004217731A1 (en) 2004-09-16
CY1108540T1 (el) 2013-09-04
US20070059773A1 (en) 2007-03-15
CA2514338A1 (en) 2004-09-16
GB0305153D0 (en) 2003-04-09
PL1604211T3 (pl) 2008-09-30
EP1604211B1 (de) 2008-04-30
DE602004013431D1 (de) 2008-06-12
PT1604211E (pt) 2008-07-04
SI1604211T1 (sl) 2008-10-31
ES2305741T3 (es) 2008-11-01
AU2004217731B2 (en) 2009-06-04
WO2004079329A2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE60329274D1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
CY1106256T1 (el) Ιοντοφορητικη χορηγηση ροτιγκοτινης για τη θepαπεια της νοσου του parkinson
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
EA200802365A1 (ru) Аминометилзамещенные тетрациклиновые соединения
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
NO20055211L (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
ATE538807T1 (de) Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin
ATE424560T1 (de) Marker für neuromyelitis optica
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
EA200400029A1 (ru) КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА АЛЬДОСТЕРОНА И ИНГИБИТОРА ГМГ-КоА-РЕДУКТАЗЫ
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
DE602006019754D1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
SE0301650D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1604211

Country of ref document: EP

REN Ceased due to non-payment of the annual fee